Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1987 Feb;60(2):173–179.

Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

S Hinuma, K Naruo, K Ootsu, T Houkan, O Shiho, K Tsukamoto
PMCID: PMC1453217  PMID: 3493209

Abstract

Recombinant human interleukin-2 (rIL-2) suppressed metastatic tumour colony formation in the lungs of C57BL/6 mice bearing Lewis lung carcinoma (3LL). In tumour-bearing mice given rIL-2, non-specific killer cells that were cytotoxic not only against natural killer-sensitive YAC-1 cells but also against 3LL cells in an in vitro 51Cr-release assay were concomitantly induced as tumour metastasis was suppressed. These non-specific killer cells were mostly removed by treatment with anti-Thy 1.2 or anti-asialo GM1 antibody plus complement (C) in vitro but not with anti-Lyt 1.2 or anti-Lyt 2.2 plus C, indicating that they were positive for Thy 1 and asialo GM1 but not for Lyt 1 and Lyt 2. In order to explore the mechanism by which rIL-2 suppressed tumour metastasis, we examined the clearance of intravenously injected 51Cr-labelled 3LL cells in the lungs of mice given rIL-2. The rate of tumour cell clearance was increased. This enhanced clearance was almost completely removed by injecting anti-asialo GM1 antibody. In addition, the injection of anti-asialo GM1 antibody also depleted most of the non-specific killer cells induced by administering rIL-2. These results indicate that asialo GM1-positive cells are not only cytotoxic in vitro but also play a critical role in the clearance of 3LL cells in the lungs in vivo. Our results indicate that asialo GM1-positive cells play an important role as anti-metastatic effector cells in suppressing the metastasis of 3LL cells in mice given rIL-2.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlozzari T., Leonhardt J., Wiltrout R. H., Herberman R. B., Reynolds C. W. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol. 1985 Apr;134(4):2783–2789. [PubMed] [Google Scholar]
  2. Chang A. E., Hyatt C. L., Rosenberg S. A. Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Mod. 1984 Oct;3(5):561–572. [PubMed] [Google Scholar]
  3. Donohue J. H., Lotze M. T., Robb R. J., Rosenstein M., Braziel R. M., Jaffe E. S., Rosenberg S. A. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 1984 Apr;44(4):1380–1386. [PubMed] [Google Scholar]
  4. Fidler I. J., Gersten D. M., Hart I. R. The biology of cancer invasion and metastasis. Adv Cancer Res. 1978;28:149–250. doi: 10.1016/s0065-230x(08)60648-x. [DOI] [PubMed] [Google Scholar]
  5. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., Tamaoki N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981 Jul;127(1):34–38. [PubMed] [Google Scholar]
  6. Hinuma S., Naruo K., Shiho O., Tsukamoto K. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. Immunology. 1986 Oct;59(2):251–259. [PMC free article] [PubMed] [Google Scholar]
  7. Hinuma S., Onda H., Naruo K., Ichimori Y., Koyama M., Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun. 1982 Nov 30;109(2):363–369. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  8. Kato K., Naruo K., Koyama M., Kawahara K., Hinuma S., Tada H., Sugino H., Tsukamoto K. Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes. Biochem Biophys Res Commun. 1985 Feb 28;127(1):182–190. doi: 10.1016/s0006-291x(85)80142-x. [DOI] [PubMed] [Google Scholar]
  9. Kato K., Yamada T., Kawahara K., Onda H., Asano T., Sugino H., Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun. 1985 Jul 31;130(2):692–699. doi: 10.1016/0006-291x(85)90472-3. [DOI] [PubMed] [Google Scholar]
  10. Kumagai K., Itoh K., Suzuki R., Hinuma S., Saitoh F. Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. J Immunol. 1982 Jul;129(1):388–394. [PubMed] [Google Scholar]
  11. Lotze M. T., Frana L. W., Sharrow S. O., Robb R. J., Rosenberg S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985 Jan;134(1):157–166. [PubMed] [Google Scholar]
  12. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984 Feb 1;159(2):495–507. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  14. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984 Sep 28;225(4669):1487–1489. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  15. Naruo K., Hinuma S., Kato K., Koyama M., Tada H., Shiho O., Tsukamoto K. Comparison of the biological properties of purified natural and recombinant human interleukin-2. Biochem Biophys Res Commun. 1985 Apr 16;128(1):257–264. doi: 10.1016/0006-291x(85)91672-9. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Mulé J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985 May 1;161(5):1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Suzuki R., Handa K., Itoh K., Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. J Immunol. 1983 Feb;130(2):981–987. [PubMed] [Google Scholar]
  18. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  19. Tsudo M., Uchiyama T., Uchino H. Expression of Tac antigen on activated normal human B cells. J Exp Med. 1984 Aug 1;160(2):612–617. doi: 10.1084/jem.160.2.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wiltrout R. H., Gorelik E., Brunda M. J., Holden H. T., Herberman R. B. Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels. Cancer Immunol Immunother. 1983;14(3):172–179. doi: 10.1007/BF00205356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wiltrout R. H., Herberman R. B., Zhang S. R., Chirigos M. A., Ortaldo J. R., Green K. M., Jr, Talmadge J. E. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol. 1985 Jun;134(6):4267–4275. [PubMed] [Google Scholar]
  22. Wiltrout R. H., Santoni A., Peterson E. S., Knott D. C., Overton W. R., Herberman R. B., Holden H. T. Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol. 1985 May;37(5):597–614. doi: 10.1002/jlb.37.5.597. [DOI] [PubMed] [Google Scholar]
  23. Yamada T., Kato K., Kawahara K., Nishimura O. Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun. 1986 Mar 28;135(3):837–843. doi: 10.1016/0006-291x(86)91004-1. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES